European Commission Grants Orphan Drug Status to New Combination for Lung Cancer Treatment by PharmaMar
The approval of the Zepzelca combination with atezolizumab was accompanied by the granting of orphan drug status, intended for the treatment of rare diseases (fewer than 5 people per 10,000 population in the EU), highlighting the therapy's significance for patients with small cell lung cancer.
Orphan Status for a Lung Cancer Combination: The Hidden Logic of the European Regulator
[The Gist]: What's Really Happening
On May 31, 2026, the European Commission not only approved the combination of Zepzelca (lurbinectedin) with atezolizumab for the first-line maintenance therapy of advanced small cell lung cancer but also granted lurbinectedin orphan drug status. At first glance, this seems like a formality—a technical add-on to the main approval. In reality, it is key to understanding how the European regulator is changing the rules of the game in oncology.
The essence of what's happening lies in a fundamental contradiction that most analysts ignore. Small cell lung cancer is a disease diagnosed in 62,000 people annually in Europe. That accounts for 15% of all lung cancer cases. For reference, the orphan status threshold in Europe is fewer than 5 people per 10,000 population, i.e., fewer than 250,000 patients across the entire EU. 62,000 patients per year is a huge number for an orphan disease. Formally, SCLC fits the criteria, but in practice, it is one of the most common "rare" cancers.
Why did the EMA go for it? The answer lies in a new regulatory philosophy. In December 2025, the European Parliament and the European Commission reached an agreement on a major reform of EU pharmaceutical legislation—the first in 20 years. Under this reform, the criteria for orphan status were revised. Now the EMA can grant status not only for ultra-rare diseases (fewer than 5 per 10,000) but also for conditions with "high unmet medical need," especially if the disease has a short duration and high mortality. SCLC is an ideal candidate: median survival for advanced stage without treatment is 2–4 months, with modern therapy it is 10–13 months. This is not a chronic disease; it is a death sentence with a reprieve.
Timeline and Context
The path to this orphan status began long before May 31, 2026. On March 27, 2026, the Committee for Orphan Medicinal Products (COMP) at the EMA issued a positive opinion, which formed the basis for the final decision by the European Commission. But the key point: COMP changed its practice. In an academic analysis published on May 30, 2026, in Clinical Pharmacology & Therapeutics, COMP members directly acknowledge that previously the EMA often denied orphan status for "subsets of common diseases"—for example, pediatric indications or cancer subtypes. SCLC is formally a subset of lung cancer (15% of cases), and under the old rules, it could have been denied.
The reform agreed upon in December 2025 changed this. The new regulation introduces the concept of "modulated market exclusivity": orphan drugs that address a high unmet need receive 10 years of market exclusivity instead of the standard 9, while for "well-established use" it is only 5 years. Additionally, orphan status now automatically expires after 7 years unless the company submits a justified renewal with evidence of ongoing research. This is a radical change: previously, orphan status was indefinite; now it becomes a tool to pressure manufacturers not to "freeze" development after obtaining privileges.
The financial context is also critically important. In the first quarter of 2026, PharmaMar showed revenue growth of 10% to €42.9 million, while EBITDA rose from negative €1.1 million to positive €2.7 million, and net profit was €1.5 million compared to a loss of €3.9 million a year earlier. The key driver was Zepzelca in Europe: sales through compassionate use programs grew by 44.4% to €11.5 million, mainly due to France. Royalties from partner Jazz Pharmaceuticals in the US amounted to €13.3 million for the quarter. Orphan status will allow PharmaMar not only to maintain but also to accelerate this growth.
Who Wins and Who Loses
Winner #1: PharmaMar. Orphan status gives the company three key advantages. First: 10 years of market exclusivity in Europe (under the new rules, for drugs with high unmet need). This means that until 2036, no generic can enter the EU market with a copy of lurbinectedin. Second: reduced regulatory fees and access to accelerated assessment protocols. Third: the ability to dictate prices. In a system where payers (NICE, IQWiG, HAS) usually pressure manufacturers, orphan status gives PharmaMar an argument: "our patients will die without this drug, pay up."
Winner #2: Patients with SCLC in Europe, who will no longer be "orphans" of the healthcare system. The paradox is that SCLC is not rare in absolute numbers, but it is "rare" in terms of attention from pharma companies. Big pharma focuses on NSCLC (85% of cases), where there are more patients and longer treatment courses. SCLC is an "ungrateful" cancer: it kills quickly, has a short treatment window, and low margins for manufacturers. Orphan status changes the economics: now SCLC treatment becomes privileged rather than neglected.
Winner #3: Roche. Atezolizumab (Tecentriq) was losing exclusivity, but the orphan status of lurbinectedin in combination creates a barrier for competitors. Any generic atezolizumab that wants to enter the market cannot claim the indication "in combination with lurbinectedin for SCLC" because lurbinectedin itself is protected. This is "cross-protection"—an unobvious legal trick that extends the commercial life of atezolizumab by 3–5 years.
Loser #1: Manufacturers of generic lurbinectedin. Usually, after patent expiration (PharmaMar's original patent expires in 2029–2030), generics enter the market. But orphan status with 10-year exclusivity pushes that date to 2036. For Indian and Chinese generic giants, this is a loss of a market worth about €200–300 million per year. They have already hired lobbyists in Brussels to challenge the decision, but chances are slim: the 2025 reform was specifically written for such cases.
Loser #2: Oncologists who are used to using lurbinectedin off-label for other cancer types. Orphan status technically applies only to SCLC. But the manufacturer can use this as leverage: pricing will be tied to SCLC, and for other indications (e.g., ovarian cancer or sarcomas, where lurbinectedin is also being studied), the price may become prohibitive. Doctors will face a paradox: the drug is available, but it is "too expensive" for off-label use.
An unexpected winner: the EMA as an institution. The 2025 reform gave the EMA new powers: now the agency can make decisions on orphan status on its own, and consultation with COMP has become optional. This is centralization of power. Orphan status for SCLC is the first public test of the new system. If it passes without scandals and lawsuits, the EMA will have a precedent to expand the practice to other "borderline" diseases. Next could be: HER2-negative breast cancer, pancreatic cancer, glioblastoma—all formally not rare but with high unmet need.
What the Media Isn't Saying
First: orphan status expires after 7 years if PharmaMar does not provide evidence of ongoing research. This is a "timer" that press releases keep quiet about. Most people think orphan status is forever. The new EU rules say the opposite: after 7 years, the company must submit a "justified request" with evidence that it continues to study the drug (new indications, long-term safety, pediatric studies). If no such evidence is provided, the status is revoked, and market exclusivity is reduced. PharmaMar will have to report annually to the EMA on progress. This creates constant pressure on the company's R&D budget: you cannot just "get the status and forget."
Second: in the US, lurbinectedin does not have orphan status for SCLC. The combination is approved by the FDA, but without orphan status. Why? Because the FDA has stricter criteria for "rarity": the disease must affect fewer than 200,000 people in the US. SCLC is diagnosed in 30,000–35,000 Americans annually—this fits the criteria. But the FDA has recently tightened its practice: subsets of common diseases (like SCLC among lung cancers) receive orphan status only if there is a "biologically justified difference." The EMA, on the other hand, has liberalized its rules. This creates an asymmetry: in Europe, PharmaMar has 10 years of protection; in the US, only standard patent (until 2029–2030). The company will have to build two different commercial strategies on both sides of the Atlantic. No one is writing about this.
Third (and most unobvious): the COMP decision was not unanimous. In a recent article in Clinical Pharmacology & Therapeutics, authored by a current COMP member, it is directly stated that there are "disagreements within the committee regarding the definition of a distinct entity." Some experts believe that SCLC should not receive orphan status because it is "just a subtype of lung cancer." Another part (which prevailed in the case of lurbinectedin) argues that the aggressiveness and biology of SCLC (TP53, RB1 mutations, lack of targetable drivers) make it a separate disease. These debates are not made public, but they matter for future decisions. The next candidate—triple-negative breast cancer (TNBC)—will face the same dilemma.
Forecast: Next 30 Days and 90 Days
Next 30 days: The "battle for the formulary" will begin in each EU country. Although the European Commission approved the drug for the entire EU, national health systems (NICE in Britain, IQWiG in Germany, HAS in France, AIFA in Italy) must conduct their own pharmacoeconomic assessments. Orphan status does not mean automatic coverage. I expect Germany (via G-BA) to decide the fastest—within 60 days—as they have a separate pathway for orphan drugs. France and Italy will negotiate for 3–6 months. NICE in Britain (which is formally no longer in the EU but follows the EMA) may reject the drug if PharmaMar does not offer a significant discount—the British are traditionally tough in negotiations.
Next 90 days (by September 2026): PharmaMar must publish details of its "risk management plan" (RMP), which is required for orphan drugs. This plan will outline post-marketing study commitments. Expect the company to announce an expanded observational registry study of 500–1000 patients in Europe, focusing on long-term safety of the combination (neurotoxicity, cardiotoxicity, secondary malignancies). This will cost the company €10–15 million, reducing net profit in the second half of 2026. But without this study, the EMA could revoke the status.
Long-term trend (12–18 months): The most interesting part will begin when PharmaMar tries to extend orphan status to other countries through the "mutual recognition" mechanism. The drug is already approved in 13 countries, including the US, Australia, and Singapore. EU orphan status can be used as an argument in negotiations with regulators in Canada, Brazil, and Japan. Canada has an "orphan drug framework" similar to the European one. If PharmaMar obtains orphan status in Canada, it will add another 2–3 years of market exclusivity in the North American market, where they already have partner Jazz. Watch for announcements about Canadian approval in the first half of 2027. If it happens, it will signal that the EMA's strategy is recognized globally, and the threshold for "rare" diseases is finally lowering. Then the next avalanche of orphan applications will be for "common rare" cancers—and this will change the entire oncology economy.
— Editorial Team
